Pharmaceutical company Alvogen revealed on Wednesday the availability of its generic equivalent of Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the US in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg and 12mg/3mg strengths.

The company said the Suboxone sublingual film is indicated for treatment of opioid dependence.

Based on Indivior SEC Filings, the US sales for Suboxone were approximately USD1.1bn in 2018.

Suboxone, which is a registered trademark of Indivior UK LLC, follows the issuance of a mandate from the US Court of Appeals for the Federal Circuit vacating the preliminary injunction that had been granted enjoining Dr. Reddy's Laboratories from marketing its product.